Mercer Global Advisors
LFCR icon

Mercer Global Advisors’s Lifecore Biomedical LFCR Stock Holding History

Mercer Global Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.71K Buy
+706
New +$3.56K ﹤0.01% 5440

Other funds holding LFCR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $292M AUM 36.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Mercer Global Advisors's LFCR Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Lifecore Biomedical (LFCR) in Q2 2026: 706 shares worth $3.71K. The stake represents ﹤0.01% of the portfolio and ranks #5440 among its holdings.

65 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Mercer Global Advisors held 706 shares of Lifecore Biomedical worth $3.71K as of Q2 2026.
  • Lifecore Biomedical was a new Mercer Global Advisors position in Q2 2026.
  • Lifecore Biomedical made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5440 holding.
  • 65 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.